Novartis Leqvio Launch Lags As COVID-19 Hinders England Access Scheme
Swiss Giant Waiting For Moratorium To Be Lifted
The CEO and head of pharma at Novartis have both cautioned against expectations of a lucrative launch for Leqvio, saying that a completely new approach to treating cholesterol lowering with a vaccine-like approach of administration twice a year will take time to get established in healthcare systems.
